Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

Shu, C. A.Goto, K.Ohe, Y.Besse, B.Park, K.Wang, Y.Griesinger, F.Yang, J. C-H.Felip, E.Sanborn, R. E.Caro, R. BernabeBauml, J. M.Chen, J.Fennema, E.Mahoney, J.Trani, L.Knoblauch, R. E.Thayu, M.Cho, B. C.2025-01-072025-01-072021-09-210923-7534https://hdl.handle.net/10668/27229enAmivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2conference outputopen access10.1016/j.annonc.2021.08.17981569-8041https://doi.org/10.1016/j.annonc.2021.08.1798700527702212